← REGULATORY CHANGES
FEDERAL REGISTER · RULEMay 9, 2025IN FORCE

Medical Devices; Hematology and Pathology Devices; Classification of the Coagulation System for the Measurement of Whole Blood Viscoelastic Properties in Perioperative Patients

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSIN FORCE
EFFECTIVEMay 9, 2025
COMMENTS CLOSE—
APPLIES TO · SPEQ TAGBiologicsDevice
Document type
Rule
Agency
Health and Human Services Department
Published
May 9, 2025
Effective
May 9, 2025
Document number
2025-08151
CFR references
21 CFR 864
Docket
FDA-2025-N-0711
ABSTRACT

The Food and Drug Administration (FDA, Agency, or we) is classifying the coagulation system for the measurement of whole blood viscoelastic properties in perioperative patients into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the coagulation system for the measurement of whole blood viscoelastic properties in perioperative patients' classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Abstract as published in the Federal Register.